Immune response to SARS-CoV-2 mRNA vaccination in multiple sclerosis patients after rituximab treatment interruption

Immune response to SARS-CoV-2 mRNA vaccination in multiple sclerosis patients after rituximab treatment interruption

Peripheral B cell depletion via anti-CD20 treatment is a highly effective disease-modifying treatment for reducing new relapses in multiple sclerosis (MS) patients. A drawback of rituximab (RTX) and other anti-CD20 antibodies is a poor immune response to vaccination. While this can be mitigated by t...

Full description

Bibliographic Details
Main Authors: Remigius Gröning, Andy Dernstedt, Clas Ahlm, Johan Normark, Peter Sundström, Mattias N. E. Forsell
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-07-01
Series:Frontiers in Immunology
Subjects:
multiple sclerosis
vaccination
COVID-19
rituximab
B cell immunology
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1219560/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1219560/full

Similar Items